New Evidence Available
Updated Recommendation
A new evidence synthesis was published:2023, Therapeutics and COVID-19: living guideline, 13 January 2023.
View latest version (2023)Bibliographic information
GuidelineTherapeutics and COVID-19: living guideline, 24 September 2021.
Year of Publication2021
Issuing InstitutionWorld Health Organization
Recommendation
Retired
Originally developed
For patients with non-severe COVID-19 (who do not meet criteria for severe or critical infection). The World Health Organisation (WHO) suggests treatment with casirivimab and imdevimab, conditional to those at highest risk of hospitalization.
Recommended in favor
Conditional
Certainty of evidence
Moderate
Also Featured In
This recommendation also appears in the following guidelines:
Guideline
Therapeutics and COVID-19. Living guideline. 7 December 2021
Year2021
InstitutionWorld Health Organization
Guideline
Therapeutics and COVID-19: living guideline, 14 January 2022.
Year2022
InstitutionWorld Health Organization